Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Under the new purchase terms, Quidel will have direct commercial responsibility for the assays run on Beckman Coulter analyzers. The deal is now valued at $680 million.
Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.
The CDC received clearance for a number of influenza panels and kits. Agilent's assay for postnatal CNV detection, and Abbott's hematocrit test were also cleared.
The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.
As part of the contract, Abbott will supply analytical equipment and consumables, including the Alinity ci and Alinity h series diagnostics instruments.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
Alere's financial results in the prior-year period reflected restatements of revenues stemming from incorrectly recorded revenue transactions.